LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027

MARKET OUTLOOK
The liquid biopsy market in Latin America has been projected to depict growth in terms of revenue and expand with a CAGR of 26.60% during the forecast years 2019-2027, according to a report by Triton Market Research.
Brazil, Mexico and countries in rest of Latin America together form the liquid biopsy market in the Latin American region.
Lung cancer is the most common type of cancer. One of the most widespread forms of lung cancer in the world is the non-small-cell lung cancer (NSCLC). Liquid biopsy tests have been instrumental in the diagnosis and detection of cancer in the early stages. Liquid biopsies performed at frequent time intervals provide thorough information regarding cancer and also suggest different therapeutic targets that benefit the overall prognosis. Also, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are the key products for liquid biopsy tests. The use of cfDNA/ctDNA can give a regular and detailed analysis of the progression or remission of cancer in real-time using a simple blood-based test. This capability is critical as new targeted drugs can be expensive. Thus, cfDNA/ctDNA is a key biomarker for liquid biopsy and development of workflows for capturing, detecting and analyzing this biomarker is a key trend in the industry.
COMPETITIVE OUTLOOK
Boston Scientific Corporation, B. Braun Melsungen AG, Roche Diagnostics Corporation, I.M.S. Internazionale Medico Scientifica Srl, Becton, Dickinson, Bio-Rad Laboratories, Inc., Cook Medical, Inc. and C. R. Bard, Inc. (acquired by Becton, Dickinson and Company) are the companies having a strong foothold in the liquid biopsy market.

TABLE OF CONTENT
1. LATIN AMERICA LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1. CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2. DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.3. TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.4. RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1. HIGH COST OF TEST
2.9.2. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10. MARKET OPPORTUNITIES
2.10.1. ADVANCEMENT IN TECHNOLOGY
2.10.2. RISING NUMBER OF CANCER PATIENTS
2.11. MARKET CHALLENGES
2.11.1. LACK OF REIMBURSEMENT
2.11.2. SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3. LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4. LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6. LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8. LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9. LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1. LATIN AMERICA
10.1.1. MARKET BY THERAPEUTIC APPLICATION
10.1.2. MARKET BY CLINICAL APPLICATION
10.1.3. MARKET BY BIOMARKER TYPE
10.1.4. MARKET BY ANALYSIS PLATFORM
10.1.5. MARKET BY ANALYSIS PURPOSE
10.1.6. MARKET BY PRODUCT
10.1.7. MARKET BY END-USER
10.1.8. COUNTRY ANALYSIS
10.1.8.1. BRAZIL
10.1.8.2. MEXICO
10.1.8.3. REST OF LATIN AMERICA
11. COMPETITIVE LANDSCAPE
11.1. AGILENT TECHNOLOGIES, INC.
11.2. BOSTON SCIENTIFIC CORPORATION
11.3. ARGON MEDICAL DEVICES, INC.
11.4. B. BRAUN MELSUNGEN AG
11.5. CINTEC MEDICAL LTD.
11.6. ROCHE DIAGNOSTICS CORPORATION
11.7. AD-TECH MEDICAL INSTRUMENT CORP.
11.8. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9. QIAGEN N.V.
11.10. BECTON, DICKINSON
11.11. PLANMECA OY
11.12. BIO-RAD LABORATORIES, INC.
11.13. CARDINAL HEALTH, INC.
11.14. COOK MEDICAL, INC.
11.15. FISCHER MEDICAL TECHNOLOGIES LLC
11.16. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1. RESEARCH SCOPE & DELIVERABLES
12.1.1. OBJECTIVES OF STUDY
12.1.2. SCOPE OF STUDY
12.2. SOURCES OF DATA
12.2.1. PRIMARY DATA SOURCES
12.2.2. SECONDARY DATA SOURCES
12.3. RESEARCH METHODOLOGY
12.3.1. EVALUATION OF PROPOSED MARKET
12.3.2. IDENTIFICATION OF DATA SOURCES
12.3.3. ASSESSMENT OF MARKET DETERMINANTS
12.3.4. DATA COLLECTION
12.3.5. DATA VALIDATION & ANALYSIS


LIST OF TABLES
TABLE 1 LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
TABLE 3 LATIN AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 4 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 5 LATIN AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 6 LATIN AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 7 LATIN AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 8 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 9 DROPLET DIGITAL PCR INDUSTRIES
TABLE 10 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 11 CELL DIFFERENTIATORS
TABLE 12 LATIN AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 13 LATIN AMERICA BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)


LIST OF FIGURES
FIGURE 1 LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 LATIN AMERICA LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 3 LATIN AMERICA LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 4 TYPES OF BREAST CANCER
FIGURE 5 LATIN AMERICA LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 6 LATIN AMERICA LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 7 LATIN AMERICA LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 8 LATIN AMERICA LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 9 LATIN AMERICA LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 10 LATIN AMERICA LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 11 LATIN AMERICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 12 LATIN AMERICA LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 13 LATIN AMERICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 14 LATIN AMERICA LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 15 LATIN AMERICA LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 16 LATIN AMERICA LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 17 LATIN AMERICA LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 18 LATIN AMERICA LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 19 LATIN AMERICA LIQUID BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 20 LATIN AMERICA LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 LATIN AMERICA LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 22 LATIN AMERICA LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 23 LATIN AMERICA LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 24 LATIN AMERICA LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 25 LATIN AMERICA LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 26 LATIN AMERICA LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 27 LATIN AMERICA LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 28 LATIN AMERICA LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 29 LATIN AMERICA LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 30 LATIN AMERICA LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 31 LATIN AMERICA LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 32 LATIN AMERICA LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 33 LATIN AMERICA LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 34 LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 35 BRAZIL LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 MEXICO LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 37 REST OF LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)